PMID: 9435876Jan 22, 1998Paper

Clinical experience with CD64-directed immunotherapy. An overview

Cancer Immunology, Immunotherapy : CII
R Curnow

Abstract

The class I IgG receptor (Fc gamma RI or CD64 receptor), which is present on key cytotoxic effector cells, has been shown to initiate the destruction of tumor cells in vitro and has been hypothesized to play a role in the destruction of antibody-coated cells such as platelets in idiopathic thrombocytopenia purpura (ITP). This overview summarizes the clinical experience with CD64-directed immunotherapy in cancer patients with the bispecific antibodies MDX-447 [humanized Fab anti-CD64 x humanized Fab anti-(epidermal growth factor receptor, EGFR)] and MDX-H210 (humanized Fab anti-DC64 x Fab anti-HER2/neu), and with the anti-CD64 monoclonal antibody (mAB) MDX-33 (H22) in the modulation of monocyte CD64 in vivo. In an ongoing phase I/II open-label trial with progressive dose escalation (1-15 mg/m2), patients with treatment refractory EGFR-positive cancers (renal cell carcinoma (RCC), head and neck, bladder, ovarian, prostate cancer and skin cancer) are treated weekly with intravenous MDX-447, with and without granulocyte-colony-stimulating factor (G-CSF). MDX-447 has been found to be immunologically active at all doses, binding to circulating monocytes and neutrophils (when given with G-CSF), causing monocytopenia and stimulating in...Continue Reading

Citations

Jul 18, 2001·Pathology Oncology Research : POR·T MagyarlakiJ Nagy
May 31, 2006·Cancer Immunology, Immunotherapy : CII·D RitchieH M Prince
Dec 6, 2001·Current Oncology Reports·Shanu Modi, Andrew D Seidman
Feb 19, 2005·Current Oncology Reports·Emiliano Calvo, Eric K Rowinsky
Feb 10, 2004·Cancer Treatment Reviews·Janessa J Laskin, Alan B Sandler
Nov 5, 2002·Clinical Biochemistry·Hassan M E Azzazy, W Edward Highsmith
Mar 22, 2003·Experimental Cell Research·Carlos L Arteaga
Aug 1, 2000·Immunology Today·A B van SprielJ G van De Winkel
Feb 5, 2003·Advanced Drug Delivery Reviews·Ying Cao, Laura Lam
Oct 11, 2003·Biotechnology Advances·A FunaroF Malavasi
Oct 6, 1999·Current Opinion in Immunology·D M SegalL M Weiner
Jan 25, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D ElsässerT Valerius
Mar 20, 2001·Critical Reviews in Oncology/hematology·H H van Ojik, T Valerius
Sep 25, 2002·Critical Reviews in Oncology/hematology·R S RampaulI O Ellis
Apr 27, 2000·Critical Reviews in Oncology/hematology·A J Bremers, G Parmiani
Feb 18, 2003·Journal of Internal Medicine·P Nygren, R Larsson
Oct 28, 2003·DNA and Cell Biology·O Guntinas-Lichius, C Wittekindt
Nov 15, 2012·Chemotherapy Research and Practice·Jeffery S Russell, A Dimitrios Colevas
Mar 19, 2014·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Ron D JachimowiczAchim Rothe
May 12, 2011·International Reviews of Immunology·Suzanne R Thibodeaux, Tyler J Curiel
Jul 1, 2010·Expert Review of Clinical Pharmacology·Jijie Gu, Tariq Ghayur
Mar 21, 2008·Expert Opinion on Biological Therapy·Esther C W Breij, Joseph J Batenburg
Dec 18, 2007·Expert Opinion on Biological Therapy·Marjolein van Egmond
Aug 26, 1998·FEBS Letters·K M MüllerA Plückthun
Jan 19, 2008·Immunology Letters·Elza FriedländerGyörgy Vereb
Jun 29, 2007·The International Journal of Biochemistry & Cell Biology·Roberto BiancoGiampaolo Tortora
Aug 10, 2004·Cancer Science·Yuji HinodaKohzoh Imai
Oct 27, 2006·International Journal of Cancer. Journal International Du Cancer·Hila NovakYoram Reiter
Jun 22, 2006·Medicinal Research Reviews·Shantaram Kamath, John K Buolamwini
Apr 2, 2004·Pharmacology & Therapeutics·Jennifer Rubin Grandis, John C Sok
Apr 28, 2004·Trends in Biotechnology·Peter KuferPatrick A Baeuerle
Nov 18, 2005·Biochemical and Biophysical Research Communications·Antje PaetzStefan Barth
Jul 5, 2005·Expert Opinion on Investigational Drugs·D L DrakemanP K Wallace
Jul 10, 2014·Pediatric Hematology and Oncology·Samin AlaviMaryam Ebadi
Dec 22, 1999·The Tohoku Journal of Experimental Medicine·T KudoS Matsuno
Jul 3, 2013·Methods : a Companion to Methods in Enzymology·Rens BrasterMarjolein van Egmond
Jan 5, 2013·Seminars in Cancer Biology·Marjolein van Egmond, Jantine E Bakema
Aug 21, 2013·Biomaterials·Chetan YewaleAmbikanandan Misra

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.